Century Therapeutics Inc

Price Chart

Risk-Adjusted Performance

Century Therapeutics Inc (IPSC) Price Performance

Century Therapeutics Inc (IPSC) trades on United States in USD. The company is classified in the Healthcare sector under the Biological Products industry. The stock currently trades at $2.24, down 7.44% from the previous close.

Over the past year, IPSC has traded between a low of $0.39 and a high of $2.73. The stock has gained 302.9% over this period. It is currently 17.9% below its 52-week high.

Century Therapeutics Inc has a market capitalization of $434.93M.

About Century Therapeutics Inc

Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.